References
- Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28.
- Krug M, Hilgeroth A. Recent advances in the development of multi-kinase inhibitors. Mini Rev Med Chem 2008;8:1312.
- Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301.
- Yang XD, Jia XC, Corvalan JRF, et al. Eradication of established tumors by a fully human monocolonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236.
- Pfister DG. The just price of cancer drugs and the growing cost of cancer care: Oncologists need to be part of the solution. J Clin Oncol 2013;31:3487.
- Lange A, Prenzler A, Frank M, et al. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer 2014;50:40.
- Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278.
- Needergard MK, Hedegaard CJ, Poulsen HS. Targeting the epidermal growth factor receptor in solid tumor malignancies. BioDrugs 2012;26:83.
- Patel R, Leung HY. Targeting the EGFR-family for therapy: biological challenges and clinical perspectives. Curr Pharm Des 2012;18:2672.
- Warnault P, Yasri A, Coisy-Quivy M, et al. Recent advances in drug design of epidermal growth factor receptor inhibitors. Curr Med Chem 2013;20:2043.
- Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. BioMed Res Int 2013;2013:546318. doi: http://dx.doi.org/10.1155/2013/54613.
- Normanno N, de Luca A, Biango C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2.
- Yun CH, Boggon TJ, Li Y, et al. Structure of lung-cancer derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217.
- Bugge S, Kaspersen SJ, Larsen S, et al. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor. Eur J Med Chem 2014;75:354.
- Andrews AF, Smith DM. Synthetic approaches to some aza-analogous of benzimidazole N-oxides. Part 1. The imidazo[4,5-b]pyridine series. J Chem Soc Perkin Trans I 1982;1:2995.
- Thutewohl M, Schirok H, Bennabi S, Figueroa-Pérez S. Synthesis of 4-substituted 7-azaindole derivatives via Pd-catalyzed C-N and C-O coupling. Synthesis. 2006;4:629.
- Witkop B. Studies on carboline anhydronium bases. J Am Chem Soc 1953;75:3361.
- Voigt B, Krug M, Schächtele C, et al. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors. ChemMedChem 2008;3:120.
- Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 2007;19:117.
- Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell 2000;103:211.
- Pawson T, Gish GD, Nash P. SH2 domains, interaction modules and cellular wiring. Trends Cell Biol 2001;11:504.
- Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest 2014;94:129.
- Wang DD, Ma L, Wong MP, et al. Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments. PLoS One 2015;10:e0128360.
- Morgillo F, Woo JJ, Kim ES, et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006;66:10100.
- Liu Y, Purvis J, Shih A, et al. A multiscale computational approach to disect early events in the Erb family receptor mediated activation, differential signaling and relevance in oncogenic transformations. Ann Biomed Engin 2007;35:1012.
- Tandon R, Senthil V, Nithya D, et al. RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy. Eur J Pharmacol 2013;711:19.